Galicaftor
- Generic Name
- Galicaftor
- Drug Type
- Small Molecule
- Chemical Formula
- C28H21F4NO7
- CAS Number
- 1918143-53-9
- Unique Ingredient Identifier
- J0IIT8QSQS
- Background
Galicaftor is under investigation in clinical trial NCT03540524 (A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.).
A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05538585
- Locations
- 🇺🇸
Clinical Pharmacology of Miami /ID# 249531, Miami, Florida, United States
🇺🇸Acpru /Id# 249532, Grayslake, Illinois, United States
A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05530278
- Locations
- 🇺🇸
Anaheim Clinical Trials LLC /ID# 248824, Anaheim, California, United States
🇺🇸Clinical Pharmacology of Miami /ID# 248823, Miami, Florida, United States
🇺🇸PPD Clinical Research Unit -Las Vegas /ID# 248853, Las Vegas, Nevada, United States
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis
- Conditions
- Cystic Fibrosis (CF)
- Interventions
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 48
- Registration Number
- NCT04853368
- Locations
- 🇺🇸
University of Southern California /ID# 249147, Los Angeles, California, United States
🇺🇸UH Cleveland Medical Center /ID# 245433, Cleveland, Ohio, United States
🇺🇸Boston Children's Hospital /ID# 248646, Boston, Massachusetts, United States
A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 78
- Registration Number
- NCT03969888
- Locations
- 🇸🇰
Univerzitna nemocnica Bratislava Nemocnica Ruzinov /ID# 213596, Bratislava, Slovakia
🇫🇷AP-HP - Hopital Cochin /ID# 212864, Paris, France
🇺🇸Medical University of South Carolina /ID# 212187, Charleston, South Carolina, United States
A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 10
- Registration Number
- NCT03540524
- Locations
- 🇳🇱
Study Site NLD002, Amsterdam, Netherlands
🇳🇱Study Site NLD001, Utrecht, Netherlands
🇧🇬Study Site BGR001, Sofia, Bulgaria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.